The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of alternate-day administration of S-1, oral leucovorin, and bevacizumab for refractory metastatic colorectal cancer.
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Chugai Pharma; Lilly; Lilly; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Hiroya Taniguchi
Honoraria - Chugai Pharma; Merck Serono; Otsuka; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); MSD; Otsuka (Inst)
 
Azusa Komori
No Relationships to Disclose
 
Seiichiro Mitani
No Relationships to Disclose
 
Hiroko Hasegawa
No Relationships to Disclose
 
Yukiya Narita
Honoraria - Lilly; Taiho Pharmaceutical; Takeda
 
Shigenori Kadowaki
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Yakult Honsha
Research Funding - Lilly Japan (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ura
No Relationships to Disclose
 
Masashi Ando
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda